Shares of biotechnology company Creative Medical Technology (NASDAQ:CELZ) are up in triple digits today after the Institutional Review Board (IRB) gave the green light for a clinical trial of the company’s product candidate CELZ-201 for the treatment of Type 1 Diabetes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The trial will be conducted at the University of Miami Health System and will evaluate CELZ-201 in newly diagnosed patients with Type 1 diabetes.
Importantly, there were 1.6 million Type 1 Diabetes patients in the U.S. in 2019 and the economic burden of the disease is pegged at $14.4 billion.
Despite today’s price gains, shares of the company are still down nearly 34% over the past year.
Read full Disclosure